Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ani Pharmaceuticals (ANIP) Assets Average (2016 - 2025)

Historic Assets Average for Ani Pharmaceuticals (ANIP) over the last 16 years, with Q3 2025 value amounting to $1.4 billion.

  • Ani Pharmaceuticals' Assets Average rose 2459.2% to $1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year increase of 2459.2%. This contributed to the annual value of $1.1 billion for FY2024, which is 3145.73% up from last year.
  • Ani Pharmaceuticals' Assets Average amounted to $1.4 billion in Q3 2025, which was up 2459.2% from $1.3 billion recorded in Q2 2025.
  • In the past 5 years, Ani Pharmaceuticals' Assets Average registered a high of $1.4 billion during Q3 2025, and its lowest value of $462.5 million during Q1 2021.
  • Its 5-year average for Assets Average is $872.5 million, with a median of $812.3 million in 2023.
  • Per our database at Business Quant, Ani Pharmaceuticals' Assets Average crashed by 148.96% in 2021 and then soared by 6393.4% in 2022.
  • Quarter analysis of 5 years shows Ani Pharmaceuticals' Assets Average stood at $621.0 million in 2021, then increased by 20.7% to $749.6 million in 2022, then increased by 19.69% to $897.2 million in 2023, then skyrocketed by 43.29% to $1.3 billion in 2024, then rose by 7.0% to $1.4 billion in 2025.
  • Its Assets Average was $1.4 billion in Q3 2025, compared to $1.3 billion in Q2 2025 and $1.3 billion in Q1 2025.